Xcovery, Betta Pharmaceuticals deal

Xcovery granted Betta (formerly Zhejiang Beta Pharma Co. Ltd.) Chinese rights to Phase I/II oncology candidate X-396. Xcovery said it will continue developing the anaplastic lymphoma kinase (ALK) i...